VYNE Therapeutics Inc.

VYNE

US92941V3087

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:58:36 2024-12-09 pm EST			5-day change	1st Jan Change
2.770 ^USD	+3.36%		-3.82%	+18.88%

Nov. 18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
Nov. 07	Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about VYNE Therapeutics Inc.

BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	Nov. 18	MT
Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	Nov. 07	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor	Sep. 12	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $198,000	Aug. 14	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 14	CI
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	Jul. 09	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index	Jun. 30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index	Jun. 30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Value Index	Jun. 30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index	Jun. 30	CI
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer	Jun. 24	CI
Arvinas, Inc. Appoints Andrew Saik as Treasurer	Jun. 24	CI
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	Jun. 13	CI
Top Premarket Gainers	Jun. 07	MT
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	Jun. 05	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	May. 09	MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	May. 06	MT
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	May. 06	CI
VYNE Therapeutics Inc. - Special Call	Apr. 04
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	Feb. 29	MT
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	CI

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-12-11 - Annual General Meeting

More about the company